» Articles » PMID: 20940197

Survival and Prognostic Factors of Early Childhood Medulloblastoma: an International Meta-analysis

Abstract

Purpose: To assess the prognostic role of clinical parameters and histology in early childhood medulloblastoma.

Patients And Methods: Clinical and histologic data from 270 children younger than age 5 years diagnosed with medulloblastoma between March 1987 and July 2004 and treated within prospective trials of five national study groups were centrally analyzed.

Results: Two hundred sixty children with medulloblastoma and specified histologic subtype were eligible for analysis (median age, 1.89 years; median follow-up, 8.0 years). Rates for 8-year event-free survival (EFS) and overall survival (OS) were 55% and 76%, respectively, in 108 children with desmoplastic/nodular medulloblastoma (DNMB) or medulloblastoma with extensive nodularity (MBEN); 27% and 42%, respectively, in 145 children with classic medulloblastoma (CMB); and 14% and 14%, respectively, in seven children with large-cell/anaplastic (LC/A) medulloblastoma (P < .001). Histology (DNMB/MBEN: hazard ratio [HR], 0.44; 95% CI, 0.31 to 0.64; LC/A medulloblastoma: HR, 2.27; 95% CI, 0.95 to 5.54; P < .001 compared with CMB), incomplete resection and metastases (M0R1: HR, 1.86; 95% CI, 1.29 to 2.80; M+: HR, 2.28; 95% CI, 1.50 to 3.46; P < .001 compared with M0R0), and national group were independent prognostic factors for EFS, and OS. The HRs for OS ranged from 0.14 for localized M0 and DNMB/MBEN to 13.67 for metastatic LC/A medulloblastoma in different national groups.

Conclusion: Our results confirm the high frequency of desmoplastic variants of medulloblastomas in early childhood and histopathology as a strong independent prognostic factor. A controlled de-escalation of treatment may be appropriate for young children with DNMB and MBEN in future clinical trials.

Citing Articles

Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179.

Li Y, Lim C, Dismuke T, Malawsky D, Oasa S, Bruce Z Nat Commun. 2025; 16(1):1091.

PMID: 39904981 PMC: 11794477. DOI: 10.1038/s41467-024-54861-3.


Case report: A second case of cerebral cavernous malformation after high-dose chemotherapy for medulloblastoma.

Pionelli M, Mazio F, Errico M, Russo C, Cristofano A, Covelli E Front Oncol. 2024; 14:1386468.

PMID: 39540155 PMC: 11557518. DOI: 10.3389/fonc.2024.1386468.


Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma.

Tsiami F, Lago C, Pozza N, Piccioni F, Zhao X, Lulsberg F Acta Neuropathol Commun. 2024; 12(1):125.

PMID: 39107797 PMC: 11304869. DOI: 10.1186/s40478-024-01831-x.


Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico.

Salceda-Rivera V, Tejocote-Romero I, Osorio D, Bellido-Magana R, Lopez-Facundo A, Anaya-Aguirre S Front Oncol. 2024; 14:1376574.

PMID: 38756654 PMC: 11096484. DOI: 10.3389/fonc.2024.1376574.


New CNS tumor classification: The importance in pediatric neurosurgical practice.

Del Rio R, Cicutti S, Moreira D, Gonzalez Ramos J Surg Neurol Int. 2024; 15:130.

PMID: 38742003 PMC: 11090558. DOI: 10.25259/SNI_681_2023.